CNSP

CNS Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website cnspharma.com
Employees(FY) 3
ISIN US18978H3003

Performance

+1.89%

-14.83%

-28.52%

-95.54%

-99.83%

YTD

-99.78%

Profile

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Advanced Technical Analysis

Technical Analysis of CNSP 2024-12-20

The stock indicators reflect a mixed sentiment, with the Moving Average Score at 30 indicating a bearish outlook, while the Oscillators Score of 53 suggests a neutral stance, and the overall Technical Score of 41 reinforces a bearish sentiment. This combination implies caution, as the prevailing indicators do not signal strong bullish momentum.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CNSP

Stock Rank

Recent News & Updates

2024-12-04 20:10
CNS Pharmaceuticals to Host Virtual Analyst and Investor Day on December 11, 2024(Accesswire)
2024-12-04 20:10
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024(Yahoo Finance)
2024-11-24 20:00
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy(Accesswire)
2024-11-17 19:55
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)(Accesswire)
2024-11-14 20:10
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results(Accesswire)
2024-11-03 20:15
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment(Accesswire)
2024-10-31 21:00
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement(Accesswire)
2024-10-23 02:50
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules(Accesswire)
2024-10-09 21:00
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment(Accesswire)
2024-10-07 21:15
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC(Accesswire)
2024-09-22 21:00
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum(Accesswire)
2024-09-11 21:00
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement(Accesswire)
2024-09-03 21:05
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Accesswire)
2024-09-02 20:00
IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.(Globenewswire)
2024-08-26 21:10
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar(Accesswire)
2024-08-21 21:15
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment(Accesswire)
2024-08-14 20:00
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results(Accesswire)
2024-07-29 19:00
CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies(Accesswire)
2024-07-24 21:05
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference(Accesswire)
2024-07-15 21:15
CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series(Accesswire)
2024-07-10 19:29
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday(Investorplace)
2024-07-02 23:10
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement(Accesswire)
2024-06-25 20:00
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement(Accesswire)
2024-06-14 03:11
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement(Accesswire)
2024-06-09 20:00
JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024(Accesswire)
2024-06-02 20:05
CNS Pharmaceuticals Announces Reverse Stock Split(Accesswire)
2024-05-19 20:30
CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase(Accesswire)
2024-05-15 23:53
CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q1 2024(Investorplace)
2024-05-15 19:45
CNS Pharmaceuticals Reports First Quarter 2024 Financial Results(Accesswire)
2024-04-22 21:00
CNS Pharmaceuticals to Present at the LSX World Congress 2024(Accesswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.